Two Pharma and Biotech Cases to Watch in 2022

“Based on the similarity of the questions presented to those that the Supreme Court declined to answer in Idenix v. Gilead, Amgen’s petition has a slim chance of success. Regardless, patent owners should be wary of asserting claims that characterize a monoclonal antibody purely on its function.” Monty Python and the Holy Grail: “I’m Not … Read more